Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand

PLoS Pathogens

Volumn 12, Issue 12, 2016, Pages

  Tomić, Adriana ^a   Varanasi, Pavankumar R ^a   Golemac, Mijo ^b   Malić, Suzana ^b   Riese, Peggy ^c   Borst, Eva M ^a   Mischak Weissinger, Eva ^a,c   Guzmán, Carlos A ^c   Krmpotić, Astrid ^b   Jonjić, Stipan ^b   Messerle, Martin ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LIGAND; LIVE VACCINE; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL EXPANSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOCUS EXPANSION ASSAY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEWBORN; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SKIN FIBROBLAST; VACCINATION; VIRUS RECOMBINANT; ANIMAL; CYTOMEGALOVIRUS; DISEASE MODEL; IMMUNOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ADAPTIVE IMMUNITY; ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; MICE; REAL-TIME POLYMERASE CHAIN REACTION; VACCINES, ATTENUATED;

EID: 85007550922     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006015     Document Type: Article

References (90)

1. Cannon MJ, Schmid DS, Hyde TB, Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202–213. doi: 10.1002/rmv.65520564615
2. Mocarski ES, Shenk T, Griffiths PD, Knipe DM, Howley PM, Cytomegaloviruses. In: Fields Virology. 6 ed.Philadelphia, PA, USA: Wolters Kluwer Lippincott Williams & Wilkins; 2013. pp. 1960–2014.
3. Lombardi G, Garofoli F, Stronati M, Congenital cytomegalovirus infection: treatment, sequelae and follow-up. J Matern Fetal Med. 2010;23(3):45–48.
4. Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP, Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect. 2011;17(9):1285–1293. doi: 10.1111/j.1469-0691.2011.03564.x21631642
5. Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ, Boppana SB, et al. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr. 2014;164(4):855–859. doi: 10.1016/j.jpeds.2013.12.00724433826
6. Ljungman P, Hakki M, Boeckh M, Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am. 2010;24(2):319–337. doi: 10.1016/j.idc.2010.01.00820466273
7. Razonable RR, Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):317–342. doi: 10.1016/j.idc.2013.02.00523714343
8. Gianella S, Massanella M, Wertheim JO, Smith DM, The sordid affair between human herpesvirus and HIV. J Infect Dis. 2015;212(6):845–852. doi: 10.1093/infdis/jiv14825748324
9. Committee to Study Priorities for Vaccine Development; Division of Health Promotion and DIsease Prevention; Institute of Medicine. Vaccines for the 21st Century: A Tool for Decisionmaking. In: Stratton KR, Durch JS, Lawrence RS, ed. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC); 2000.
10. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R, Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004;39(2):233–239. doi: 10.1086/42199915307033
11. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, et al. Priorities for CMV vaccine development. Vaccine. 2013;32(1):4–10. doi: 10.1016/j.vaccine.2013.09.04224129123
12. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191–1199. doi: 10.1056/NEJMoa080474919297572
13. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256–1263. doi: 10.1016/S0140-6736(11)60136-021481708
14. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science. 2013;340(6135):1237874. doi: 10.1126/science.123787423704576
15. Trsan T, Busche A, Abram M, Wensveen FM, Lemmermann NA, Arapovic M, et al. Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1gamma. Proc Natl Acad Sci USA. 2013;110(41):16550–16555. doi: 10.1073/pnas.131021511024052528
16. Redwood AJ, Messerle M, Harvey NL, Hardy CM, Koszinowski UH, Lawson MA, et al. Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception. J Virol. 2005;79(5):2998–3008. doi: 10.1128/JVI.79.5.2998-3008.200515709020
17. Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, et al. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J Immunother. 2012;35(5):390–399. doi: 10.1097/CJI.0b013e3182585d5022576344
18. Beverley PC, Ruzsics Z, Hey A, Hutchings C, Boos S, Bolinger B, et al. A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis. J Immunol. 2014;193(5):2306–2316. doi: 10.4049/jimmunol.130252325070842
19. Qiu Z, Huang H, Grenier JM, Perez OA, Smilowitz HM, Adler B, et al. Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8(+) T-cell response and protects mice from melanoma. Cancer Immunol Res. 2015;3(5):536–546. doi: 10.1158/2326-6066.CIR-14-004425633711
20. Karrer U, Wagner M, Sierro S, Oxenius A, Hengel H, Dumrese T, et al. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol. 2004;78(5):2255–2264. doi: 10.1128/JVI.78.5.2255-2264.200414963122
21. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME, Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008;5:47. doi: 10.1186/1743-422X-5-4718371229
22. Schleiss MR, Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008;325:361–382. 18637516
23. Griffiths P, Plotkin S, Mocarski E, Pass R, Schleiss M, Krause P, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine. 2013;31(2):197–203.
24. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de Carvalho e Oliveira PF, Boppana S, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis. 2009;49(4):522–528. doi: 10.1086/60088219583520
25. Yamamoto AY, Mussi-Pinhata MM, Isaac Mde L, Amaral FR, Carvalheiro CG, Aragon DC, et al. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. Pediatr Infect Dis J. 2011;30(12):1043–1046. doi: 10.1097/INF.0b013e31822d964021814153
26. Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet. 1984;1(8376):528–530. 6142252
27. Plotkin SA, Vaccination against cytomegalovirus. Arch Virol Suppl. 2001;(17):121–134. 11339541
28. Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis. 2006;193(10):1350–1360. doi: 10.1086/50336516619181
29. Adler SP, Manganello AM, Lee R, McVoy MA, Nixon DE, Plotkin S, et al. A phase 1 study of four live, recombinant human cytomegalovirus Towne/Toledo chimera vaccines in CMV seronegative men. J Infect Dis. 2016. 27521362
30. Cicin-Sain L, Bubic I, Schnee M, Ruzsics Z, Mohr C, Jonjic S, et al. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol. 2007;81(24):13825–13834. doi: 10.1128/JVI.01911-0717913824
31. Crumpler MM, Choi KY, McVoy MA, Schleiss MR, A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Vaccine. 2009;27(31):4209–4218. doi: 10.1016/j.vaccine.2009.04.03619389443
32. Slavuljica I, Busche A, Babic M, Mitrovic M, Gasparovic I, Cekinovic D, et al. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest. 2010;120(12):4532–4545. doi: 10.1172/JCI4396121099111
33. Mestas J, Hughes CC, Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731–2738. 14978070
34. Miller-Kittrell M, Sparer TE, Feeling manipulated: cytomegalovirus immune manipulation. Virol J. 2009;6:4. doi: 10.1186/1743-422X-6-419134204
35. Rawlinson WD, Farrell HE, Barrell BG, Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol. 1996;70(12):8833–8849. 8971012
36. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, et al. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol. 2008;89(Pt 2):359–368. doi: 10.1099/vir.0.83286-018198366
37. Halenius A, Gerke C, Hengel H, Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets-but how many arrows in the quiver?Cell Mol Immunol. 2015;12(2):139–153. doi: 10.1038/cmi.2014.10525418469
38. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123–133. 11239445
39. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol. 2003;33(1):194–203. doi: 10.1002/immu.20039002212594848
40. Vales-Gomez M, Browne H, Reyburn HT, Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells. BMC Immunology. 2003;4:4. doi: 10.1186/1471-2172-4-412694635
41. Wu Z, Sinzger C, Reichel JJ, Just M, Mertens T, Natural killer cells can inhibit the transmission of human cytomegalovirus in cell culture by using mechanisms from innate and adaptive immune responses. J Virol. 2015;89(5):2906–2917. doi: 10.1128/JVI.03489-1425540381
42. Fujiwara S, Imadome K, Takei M, Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp Mol Med. 2015;47:e135. doi: 10.1038/emm.2014.8825613732
43. Denton PW, Garcia JV, Humanized mouse models of HIV infection. AIDS Reviews. 2011;13(3):135–148. 21799532
44. Smith MS, Goldman DC, Bailey AS, Pfaffle DL, Kreklywich CN, Spencer DB, et al. Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe. 2010;8(3):284–291. doi: 10.1016/j.chom.2010.08.00120833379
45. Tanaka S, Saito Y, Kunisawa J, Kurashima Y, Wake T, Suzuki N, et al. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rgammaKO mice. J Immunol. 2012;188(12):6145–6155. doi: 10.4049/jimmunol.110366022611244
46. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA. 2011;108(36):14725–14732. doi: 10.1073/pnas.111090010821825173
47. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012;119(11):2665–2674. doi: 10.1182/blood-2011-10-38699522180440
48. Schleiss MR, Cytomegalovirus in the neonate: immune correlates of infection and protection. Clin Dev Immunol. 2013;2013:501801. doi: 10.1155/2013/50180124023565
49. Legrand N, Weijer K, Spits H, Experimental models to study development and function of the human immune system in vivo. J Immunol. 2006;176(4):2053–2058. 16455958
50. Becker PD, Legrand N, van Geelen CM, Noerder M, Huntington ND, Lim A, et al. Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice. PloS One. 2010;5(10). 20957227
51. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z, Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood. 2002;99(8):2913–2921. 11929782
52. Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW, Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood. 2004;103(11):4207–4215. doi: 10.1182/blood-2003-12-435014962896
53. Djaoud Z, David G, Bressollette C, Willem C, Rettman P, Gagne K, et al. Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. J Immunol. 2013;191(5):2708–2716. doi: 10.4049/jimmunol.130113823918974
54. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T, Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001;2(3):255–260. doi: 10.1038/8532111224526
55. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F, NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol. 2005;174(8):4480–4484. 15814668
56. Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol. 2005;175(2):720–729. 16002667
57. Andoniou CE, van Dommelen SL, Voigt V, Andrews DM, Brizard G, Asselin-Paturel C, et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol. 2005;6(10):1011–1019. doi: 10.1038/ni124416142239
58. Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA, Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol. 2003;4(2):175–181. doi: 10.1038/ni88012496964
59. Robbins SH, Bessou G, Cornillon A, Zucchini N, Rupp B, Ruzsics Z, et al. Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog. 2007;3(8):e123. doi: 10.1371/journal.ppat.003012317722980
60. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M, Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity. 2010;33(6):955–966. doi: 10.1016/j.immuni.2010.11.02021130004
61. Su HC, Nguyen KB, Salazar-Mather TP, Ruzek MC, Dalod MY, Biron CA, NK cell functions restrain T cell responses during viral infections. Eur J Immunol. 2001;31(10):3048–3055. doi: 10.1002/1521-4141(2001010)31:10&60;3048::AID-IMMU3048&62;3.0.CO;2-111592081
62. Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med. 2010;207(6):1333–1343. doi: 10.1084/jem.2009119320513749
63. Hambach L, Nijmeijer BA, Aghai Z, Schie ML, Wauben MH, Falkenburg JH, et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia. 2006;20(2):371–374. doi: 10.1038/sj.leu.240405616357839
64. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol. 2008;41(3):206–212. doi: 10.1016/j.jcv.2007.10.02718069056
65. Chijioke O, Muller A, Feederle R, Barros MH, Krieg C, Emmel V, et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Reports. 2013;5(6):1489–1498. doi: 10.1016/j.celrep.2013.11.04124360958
66. Sinzger C, Digel M, Jahn G, Cytomegalovirus cell tropism. Curr Top Microbiol Immunol. 2008;325:63–83. 18637500
67. Crawford LB, Streblow DN, Hakki M, Nelson JA, Caposio P, Humanized mouse models of human cytomegalovirus infection. Curr Opin Virol. 2015;13:86–92. doi: 10.1016/j.coviro.2015.06.00626118890
68. Sharma A, Wu W, Sung B, Huang J, Tsao T, Li X, et al. Respiratory Syncytial Virus (RSV) pulmonary infection in humanized mice induces human anti-RSV immune responses and pathology. J Virol. 2016;90(10):5068–5074. doi: 10.1128/JVI.00259-1626962219
69. Jaiswal S, Smith K, Ramirez A, Woda M, Pazoles P, Shultz LD, et al. Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med. 2015;240(1):67–78. 25125497
70. Jaiswal S, Pazoles P, Woda M, Shultz LD, Greiner DL, Brehm MA, et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology. 2012;136(3):334–343. doi: 10.1111/j.1365-2567.2012.03585.x22384859
71. Seung E, Tager AM, Humoral immunity in humanized mice: a work in progress. J Infect Dis. 2013;208(2):155–159. 24151323
72. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV, Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol. 2008;324:149–165. 18481459
73. Hesse J, Ameres S, Besold K, Krauter S, Moosmann A, Plachter B, Suppression of CD8+ T-cell recognition in the immediate-early phase of human cytomegalovirus infection. J Gen Virol. 2013;94(Pt 2):376–386. doi: 10.1099/vir.0.045682-023100361
74. Ameres S, Besold K, Plachter B, Moosmann A, CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity. J Immunol. 2014;192(12):5894–5905. doi: 10.4049/jimmunol.130228124808364
75. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001;167(10):5527–5530. 11698420
76. Muntasell A, Magri G, Pende D, Angulo A, Lopez-Botet M, Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood. 2010;115(25):5170–5179. doi: 10.1182/blood-2009-11-25647920393128
77. Cerboni C, Ardolino M, Santoni A, Zingoni A, Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Blood. 2009;113(13):2955–2964. doi: 10.1182/blood-2008-06-16594419124832
78. Groh V, Wu J, Yee C, Spies T, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–738. doi: 10.1038/nature0111212384702
79. Song H, Kim J, Cosman D, Choi I, Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 2006;239(1):22–30. doi: 10.1016/j.cellimm.2006.03.00216630603
80. Iezzi G, Karjalainen K, Lanzavecchia A, The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 1998;8(1):89–95. 9462514
81. Cheney EE, Wise EL, Bui JD, Schreiber RD, Carayannopoulos LN, Spitzer D, et al. A dual function of NKG2D ligands in NK-cell activation. Eur J Immunol. 2012;42(9):2452–2458. doi: 10.1002/eji.20114184922740149
82. Mohr CA, Arapovic J, Muhlbach H, Panzer M, Weyn A, Dolken L, et al. A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J Virol. 2010;84(15):7730–7742. doi: 10.1128/JVI.02696-0920463067
83. Snyder CM, Cho KS, Bonnett EL, Allan JE, Hill AB, Sustained CD8+ T cell memory inflation after infection with a single-cycle cytomegalovirus. PLoS Pathog. 2011;7(10):e1002295. doi: 10.1371/journal.ppat.100229521998590
84. Schleiss MR, Stroup G, Pogorzelski K, McGregor A, Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. Vaccine. 2006;24(37–39):6175–6186. doi: 10.1016/j.vaccine.2006.06.07716879902
85. Choi KY, Root M, McGregor A, A novel non-replication competent cytomegalovirus capsid mutant vaccine strategy is effective in reducing congenital infection. J Virol. 2016; 90(17):7902–7919. 27334585
86. Glass M, Busche A, Wagner K, Messerle M, Borst EM, Conditional and reversible disruption of essential herpesvirus proteins. Nat Methods. 2009;6(8):577–579. doi: 10.1038/nmeth.134619578384
87. Sallusto F, Lanzavecchia A, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109–1118. 8145033
88. Sprenger A, Kuttner V, Biniossek ML, Gretzmeier C, Boerries M, Mack C, et al. Comparative quantitation of proteome alterations induced by aging or immortalization in primary human fibroblasts and keratinocytes for clinical applications. Mol Biosyst. 2010;6(9):1579–1582. doi: 10.1039/c003962d20454738
89. Borst EM, Benkartek C, Messerle M, Use of bacterial artificial chromosomes in generating targeted mutations in human and mouse cytomegaloviruses. Curr Protoc Immunol. 2007;Chapter 10:Unit 10.32. 18432982
90. Novak Z, Chowdhury N, Ross SA, Pati SK, Fowler K, Boppana SB, Diagnostic consequences of cytomegalovirus glycoprotein B polymorphisms. J Clin Microbiol. 2011;49(8):3033–3035. doi: 10.1128/JCM.01039-1121653769